About 6 results found for searched term "JAK1-IN-11" (0.121 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M41708 | JAK1-IN-11 | JAK |
| JAK1-IN-11 is a potent inhibitor of JAK, with IC50s of 0.02 nM (JAK1), and 0.44 nM (JAK2), respectively. | ||
| M1700 | Momelotinib (CYT387) | JAK |
| LM-1149; Momelotinib; CYT 11387 | ||
| Momelotinib (CYT387) is a small-molecule, ATP-competitive JAK1/JAK2 inhibitor with IC50 of 11 and 18 nM respectively. | ||
| M4912 | GLPG0634 analogue | JAK |
| GLPG0634 analogue is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively. | ||
| M7551 | Solcitinib | JAK |
| GSK-2586184; GLPG-0778 | ||
| Solcitinib is an oral, competitive, potent, and selective JAK1 inhibitor with an IC50 value of 9.8 nM, which is 11,55, and 23 times more selective than JAK2, JAK3, and TYK2. Solcitinib can be used in studies of psoriasis. | ||
| M49577 | JAK1-IN-8 | JAK |
| JAK1-IN-8, a potent JAK1 inhibitor (IC50<500 nM), compound 28, extracted from patent WO2016119700A1. | ||
| M49586 | JAK3 covalent inhibitor-1 | JAK |
| JAK3 covalent inhibitor-1 is a potent and selective janus kinase 3 (JAK3) covalent inhibitor with an IC50 of 11 nM and shows 246-fold selectivity vs other JAKs. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
